Amgen Inc. (AMGN)

177.96
1.98 1.10
NASDAQ : Health Technology
Prev Close 179.94
Open 180.00
Day Low/High 176.99 / 180.26
52 Wk Low/High 153.56 / 201.23
Volume 2.36M
Avg Volume 4.73M
Exchange NASDAQ
Shares Outstanding 666.00M
Market Cap 117.53B
EPS 2.70
P/E Ratio 56.62
Div & Yield 5.28 (2.70%)

Latest News

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Here's what you need to know now for Friday, May 18.

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

Aimovig is the first treatment approved by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor.

FDA Approves Aimovig™ (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention

Migraine is a Severe Neurologic Disease That Profoundly Impacts Millions of Patients in the United States

Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease

New Indication Supports Amgen's Commitment to Reduce the Risk of Recurrent Cardiovascular Events Faced by Heart Attack and Stroke Survivors

Amgen Becomes #44 Most Shorted Nasdaq 100 Component, Replacing Ulta Beauty

The most recent short interest data has been released for the 04/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Waste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning Round

Waste Management, Blackstone Group, Xilinx: 'Mad Money' Lightning Round

Jim Cramer weighs in on Waste Management, Blackstone Group, Xilinx, Celgene, Nvidia, Exelixis, Moneygram and more.

Trump, Trade and Tariffs: Cramer's 'Mad Money' Recap (Thursday 5/3/18)

Trump, Trade and Tariffs: Cramer's 'Mad Money' Recap (Thursday 5/3/18)

Jim Cramer thinks that, finally, bargain hunters are just saying, "Enough already! It can't be that bad."

Teva Shows Progress on Restructuring But Investors Want More

Teva Shows Progress on Restructuring But Investors Want More

The Israel-based drugmaker reported first-quarter numbers that surpassed analysts' expectations but Wall Street wants to see more.

Jim Cramer: Are Markets Getting Tired of Trump, Trade and Tariffs?

Jim Cramer: Are Markets Getting Tired of Trump, Trade and Tariffs?

Sooner or later, bargain hunters will say: 'Enough already. It can't be that bad.'

Haters Gonna Hate: Cramer's 'Mad Money' Recap (Wednesday 5/2/18)

Haters Gonna Hate: Cramer's 'Mad Money' Recap (Wednesday 5/2/18)

We have a wall of worry to overcome, but it's important to hear the other side of the trade, says Jim Cramer. Take Apple and Facebook, for example.

Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label

KYPROLIS is the First and Only Relapsed or Refractory Multiple Myeloma Treatment to Demonstrate Overall Survival in two Phase 3 Studies

Feels Like the Semis Are Skating on Thin Ice: Market Recon

Feels Like the Semis Are Skating on Thin Ice: Market Recon

Forward looking valuations, except for Nvidia, are very low.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

These 2 Widely Held Stocks Look Good Short

These 2 Widely Held Stocks Look Good Short

Our 'bearish bets' show weak technical characteristics and have received recent quant downgrades.

Amgen’s Chart Needs a New Drug, Plus 4 Other Bearish Bets

AMGN, BIG, BSET, YRD and CRUS were all recently downgraded by TheStreet's Quant Ratings service.

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: BAM, BBBY, LMNR, TCAP Downgrades: AMGN, HQCL, HRZN, MRCC, NMFC, PAR, PKOH, SHLM, SSB, TEDU, UBSI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.

European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma

This Approval was Based on the Largest International Trial Ever Conducted for the Prevention of Skeletal-Related Events in Multiple Myeloma Patients

FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children

FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children

BLINCYTO is the First-and-Only FDA-Approved Therapy for Minimal Residual Disease

Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes

Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (evolocumab) Prevents Heart Attacks And Strokes

Recommended Label Includes New Indication Based on the Repatha Cardiovascular Outcomes Study (FOURIER)

Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer

Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin®) For The Treatment Of Three Types Of Cancer

Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab)

New Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events

New Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events

Research Presented at American College of Cardiology's 67th Annual Scientific Session Reveals More Than 110,000 Cardiovascular Events a Year Could Occur in High-Risk Patients With Cardiovascular Disease who are Rejected Access

TheStreet Quant Rating: C+ (Hold)